Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN to use Stroke research to accelerate TBI study

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Feb 23, 2023 3:52pm

146 Views

Post# 35301795

AGN to use Stroke research to accelerate TBI study

Algernon Pharmaceuticals' (AGN.c AGNPF) subsidiary, AGN Neuro, has added a new clinical research program to investigate treating Traumatic Brain Injury with DMT.

AGN hopes to use data from its ongoing DMT-Stroke study to accelerate directly into a Phase 2 TBI study in Q4, 2023.

https://ca.finance.yahoo.com/news/algernon-neuroscience-initiates-traumatic-brain-120000497.html

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide